PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award

BOSTON, April 23, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that its Chief Operating Officer (COO), Mark A. Goldberg, M.D., was honored by the Academy of Physicians in Clinical Research (APCR). Dr. Goldberg was recognized for his contributions to the advancement of clinical research during the awards ceremony and reception at the Association of Clinical Research Professionals (ACRP) 2012 Global Conference & Exhibition in Houston, Texas on April 15, 2012.

Dr. Goldberg was honored with this year's APCR Special Recognition Award for his embodiment of APCR's values and for the advancement of clinical research by combining his medical knowledge and development expertise with the application of information technology.  For nearly two decades, he has pursued a vision to help biopharmaceutical companies leverage information technology to improve decision making and bring efficiencies to clinical development.  COO since 2008, Dr. Goldberg has been an asset to PAREXEL's executive management team for 15 years. In 2000, he was involved in establishing Perceptive Informatics, PAREXEL's technology subsidiary and a leading eClinical solutions provider, to deliver advanced technology solutions.  Prior to being appointed COO, Dr. Goldberg led strong performance in Clinical Research Services, PAREXEL's largest business segment, and oversaw the geographic expansion of PAREXEL's services, including the extension of capabilities in the Asia-Pacific region.

"I am honored by this recognition from the APCR, the leading professional organization dedicated to supporting and addressing the unique issues and challenges of physicians in clinical research," said Dr. Goldberg. "This award is a testament to PAREXEL's longstanding vision of leveraging information technology to improve efficiency and effectiveness throughout the clinical development process." 

Prior to PAREXEL, Dr. Goldberg served as president and director of WorldCare, Inc., a telehealth spin off from Massachusetts General Hospital.  He holds a degree in computer science and engineering from the Massachusetts Institute of Technology, and earned his medical degree from the University of Massachusetts Medical School.

The APCR Special Recognition Award is presented annually to an individual who has demonstrated exceptional performance, achievement and sustained service toward the goals of the APCR, and has made significant contributions to the betterment of the APCR overall. Past recipients include: Senator Edward Kennedy in 2008, Robert J. Levine in 2009, Robert M. Califf in 2010 and Carl Peck in 2011. More information about the APCR Awards can be found at www.acrp2012.org.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 11,300 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $2.0 million in the third quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2011 as filed with the SEC on February 9, 2012, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

SOURCE PAREXEL International Corporation